These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36495880)

  • 81. Certolizumab pegol for the treatment of psoriatic arthritis.
    Hansen RB; Kavanaugh A
    Expert Rev Clin Immunol; 2015 Mar; 11(3):307-18. PubMed ID: 25651776
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review.
    Barešić M; Smiljanić Tomičević L; Anić B; Mayer M
    Rheumatol Int; 2022 Feb; 42(2):365-370. PubMed ID: 35022831
    [TBL] [Abstract][Full Text] [Related]  

  • 83. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
    Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
    Front Immunol; 2020; 11():1894. PubMed ID: 32973785
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.
    Costa L; Caso F; Cantarini L; Del Puente A; Scarpa R; Atteno M
    Clin Rheumatol; 2014 Sep; 33(9):1355-7. PubMed ID: 24705820
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Psoriatic uveitis responding to adalimumab therapy.
    Ermertcan AT; Emre S; Öztürk F; Gençoğlan G; Gündüz K
    Int J Dermatol; 2014 Apr; 53(4):e271-3. PubMed ID: 23879868
    [No Abstract]   [Full Text] [Related]  

  • 87. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis.
    Khosravi-Hafshejani T; Zhou Y; Dutz JP
    J Rheumatol; 2019 Apr; 46(4):437-438. PubMed ID: 30936225
    [No Abstract]   [Full Text] [Related]  

  • 89. Factors associated with the prescription of "traditional" or "biological" systemic treatment in psoriasis.
    Tabolli S; Paradisi A; Giannantoni P; Gubinelli E; Abeni D
    J Dermatolog Treat; 2015 Feb; 26(1):37-40. PubMed ID: 24559128
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Aphthous Stomatitis in a Man with Psoriatic Arthritis.
    Fermon C; Gerfaud-Valentin M; Durupt F; Sève P
    Am J Med; 2021 Jun; 134(6):749-750. PubMed ID: 33607089
    [No Abstract]   [Full Text] [Related]  

  • 91. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
    Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
    Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Paradoxical cutaneous reactions associated with tocilizumab therapy].
    Sparsa L; Afif N; Bularca S; Fricker A; Thiebault S; Dahan E; Wendling D; Sibilia J; Ardizzone M
    Rev Med Interne; 2014 Sep; 35(9):613-6. PubMed ID: 24630585
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
    Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Therapy: Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy?
    Onuora S
    Nat Rev Rheumatol; 2014 Mar; 10(3):125. PubMed ID: 24535545
    [No Abstract]   [Full Text] [Related]  

  • 97. Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis.
    Koga T; Matoba M; Sato T; Koike Y; Endo Y; Sumiyoshi R; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kawakami A
    Clin Immunol; 2018 Dec; 197():107-109. PubMed ID: 30248399
    [No Abstract]   [Full Text] [Related]  

  • 98. Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects.
    Waddington JC; Coleman O; Mease PJ; Chandran V; O'Sullivan D; FitzGerald O; Pennington SR
    J Rheumatol; 2022 Jun; 49(6 Suppl 1):13-15. PubMed ID: 35365582
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A case of nail psoriasis-associated psoriatic arthritis successfully treated with adalimumab.
    Ikumi N; Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Kuwana Y; Matsukawa Y; Hayama T; Sawada S; Takei M; Ochiai T
    Acta Dermatovenerol Croat; 2014; 22(1):65-6. PubMed ID: 24813847
    [No Abstract]   [Full Text] [Related]  

  • 100. [Novel biologics in treatment of psoriatic arthritis].
    ZHOU J; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):404-8. PubMed ID: 19693980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.